Peptide Atlas · Peptide

Pemvidutide

Pemvidutide is a GLP-1 and glucagon dual receptor agonist; in a 12-week randomized trial in 94 people with metabolic dysfunction-associated steatotic liver disease, weekly injections cut liver fat by 46.6% to 68.5% from baseline against 4.4% on placebo.

emerging

provisional
1 citation
0 discussions
0 followers
ALT-801

Follow this molecule Ask the Hunter-Gatherer

What the evidence says

six tiers, never blended

emerging — human data exists, and it is thin or contested

every claim resolves to its source

All 1 citation resolves to their original source. · 0 posts naming it, 0 members counted once each.

- emerging
  Claim: Pemvidutide reduced liver fat content over 12 weeks in MASLD (RCT, n=94) standing
- resolved
Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study.
Harrison SA, Browne SK, Suschak JJ, Tomah S, Gutierrez JA, Yang J, Roberts MS, Harris MS
pmid 39002641

A claim's standing is its latest row in an append-only history; a tombstone names the later evidence and the reason. The Graveyard and the Resurrection Yard.

Negative findings

failure is information

Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.